metoprolol has been researched along with Lassitude in 21 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We looked at evidence of clinical deterioration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) by analyzing events and symptoms during the first 90 days." | 9.10 | Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). ( Deedwania, P; Fisher, ML; Gottlieb, SS; Gullestad, L; Kjekshus, J; Vitovec, J; Wikstrand, J, 2002) |
| "A double-blind crossover trial was undertaken to compare the efficacy of sustained-release clonidine and long-acting propranolol in the treatment of 20 patients (8 males and 12 females) with sustained hypertension." | 9.05 | Comparison of sustained-release clonidine and long-acting propranolol in the treatment of hypertension. ( Lawson, AA; Rodrigues, E, 1982) |
| "The effect of metoprolol, a beta1-selective receptor blocking agent without intrinsic stimulating activity, on blood pressure, pulse and plasma concentration 2 and 24 h after dose intake and on working capacity and perceived exertion 2 h after dose intake was investigated when given as 100 mg and 200 mg conventional tablets or 200 mg slow-release tablets (Durules) once daily, long-term, to 20 patients with primary (essential) hypertension." | 9.05 | Metoprolol administered once daily in the treatment of hypertension. A double-blind crossover comparison between conventional tablets and metoprolol Durules. ( Asplund, J; Ohman, P, 1981) |
| "When metoprolol responses were compared with those for atenolol, changes in exercise time and fatigue scores were significantly related to oxidation phenotype." | 6.67 | Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. ( Jackson, PR; Lennard, MS; Lewis, RV; Ramsay, LE; Tucker, GT; Yeo, WW, 1991) |
| "The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two beta-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes." | 5.12 | beta-blocker use and diabetes symptom score: results from the GEMINI study. ( Anderson, KM; Bakris, GL; Bell, DS; Dalal, MR; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "We looked at evidence of clinical deterioration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) by analyzing events and symptoms during the first 90 days." | 5.10 | Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). ( Deedwania, P; Fisher, ML; Gottlieb, SS; Gullestad, L; Kjekshus, J; Vitovec, J; Wikstrand, J, 2002) |
| "After 4 days of drug treatment with comparable doses of propranolol (40 and 80 mg), metoprolol (50 and 100 mg), or placebo, mood (POMS) and anxiety states (STAI) were assessed in healthy volunteers, before and after 1 h of treadmill walking exercise at 50% maximum oxygen uptake." | 5.08 | Acute effects of beta blockade and exercise on mood and anxiety. ( Eagles, C; Ferner, R; Head, A; Kendall, MJ, 1996) |
| "A double-blind crossover trial was undertaken to compare the efficacy of sustained-release clonidine and long-acting propranolol in the treatment of 20 patients (8 males and 12 females) with sustained hypertension." | 5.05 | Comparison of sustained-release clonidine and long-acting propranolol in the treatment of hypertension. ( Lawson, AA; Rodrigues, E, 1982) |
| "The effect of metoprolol, a beta1-selective receptor blocking agent without intrinsic stimulating activity, on blood pressure, pulse and plasma concentration 2 and 24 h after dose intake and on working capacity and perceived exertion 2 h after dose intake was investigated when given as 100 mg and 200 mg conventional tablets or 200 mg slow-release tablets (Durules) once daily, long-term, to 20 patients with primary (essential) hypertension." | 5.05 | Metoprolol administered once daily in the treatment of hypertension. A double-blind crossover comparison between conventional tablets and metoprolol Durules. ( Asplund, J; Ohman, P, 1981) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1." | 2.71 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. ( Charlesworth, A; Cleland, JG; Ekman, I; Metra, M; Poole-Wilson, PA; Swedberg, K, 2005) |
| "When metoprolol responses were compared with those for atenolol, changes in exercise time and fatigue scores were significantly related to oxidation phenotype." | 2.67 | Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. ( Jackson, PR; Lennard, MS; Lewis, RV; Ramsay, LE; Tucker, GT; Yeo, WW, 1991) |
| " The metoprolol CR formulation displayed an even plasma concentration-time profile over the dosage interval while atenolol produced a peak at 2-4 h." | 2.67 | Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol. ( Dahlöf, CG; Dimenäs, ES; Heibel, B; Lücker, PW; Moore, RG; Olofsson, BK; Westergren, GE, 1990) |
| "Pharmacokinetic and pharmacodynamic properties of a new controlled-release (CR) formulation of metoprolol have been compared with those of atenolol." | 2.66 | Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol. ( Blomqvist, I; Jonsson, UE; Lundborg, P; Sandberg, A; Westergren, G, 1988) |
| "Supraventricular tachycardia is uncommon in pregnancy." | 1.40 | Management of labour and delivery in a woman with refractory supraventricular tachycardia. ( Dennis, AT; Gerstman, MD, 2014) |
| "Metoprolol is a selective β-1 adrenergic receptor blocker that undergoes extensive metabolism by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6)." | 1.40 | Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. ( Burkley, BM; Chapman, AB; Cooper-DeHoff, RM; Dwivedi, R; Garcia, S; Gong, Y; Gums, JG; Hamadeh, IS; Johnson, JA; Langaee, TY; Skaar, TC; Turner, ST, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (47.62) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duricova, J | 1 |
| Perinova, I | 1 |
| Jurckova, N | 1 |
| Kacirova, I | 1 |
| Grundmann, M | 1 |
| Dennis, AT | 1 |
| Gerstman, MD | 1 |
| Hamadeh, IS | 1 |
| Langaee, TY | 1 |
| Dwivedi, R | 1 |
| Garcia, S | 1 |
| Burkley, BM | 1 |
| Skaar, TC | 1 |
| Chapman, AB | 1 |
| Gums, JG | 1 |
| Turner, ST | 1 |
| Gong, Y | 1 |
| Cooper-DeHoff, RM | 1 |
| Johnson, JA | 1 |
| Paul, S | 1 |
| Trupp, RJ | 1 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Ekman, I | 1 |
| Cleland, JG | 1 |
| Swedberg, K | 1 |
| Charlesworth, A | 1 |
| Metra, M | 1 |
| Poole-Wilson, PA | 1 |
| McGill, JB | 1 |
| Bakris, GL | 1 |
| Fonseca, V | 1 |
| Raskin, P | 1 |
| Messerli, FH | 1 |
| Phillips, RA | 1 |
| Katholi, RE | 1 |
| Wright, JT | 1 |
| Iyengar, M | 1 |
| Anderson, KM | 1 |
| Lukas, MA | 1 |
| Dalal, MR | 1 |
| Bell, DS | 1 |
| Fellenius, E | 1 |
| Schnabel, A | 1 |
| Kindermann, W | 1 |
| Steinkraus, V | 1 |
| Salas-Fraire, O | 1 |
| Biro, G | 1 |
| Weiner, L | 1 |
| Rössner, S | 1 |
| Rodrigues, E | 1 |
| Lawson, AA | 1 |
| Asplund, J | 1 |
| Ohman, P | 1 |
| Head, A | 1 |
| Kendall, MJ | 1 |
| Ferner, R | 1 |
| Eagles, C | 1 |
| Gottlieb, SS | 1 |
| Fisher, ML | 1 |
| Kjekshus, J | 2 |
| Deedwania, P | 1 |
| Gullestad, L | 2 |
| Vitovec, J | 1 |
| Wikstrand, J | 1 |
| Anderson, SD | 1 |
| Bye, PT | 1 |
| Perry, CP | 1 |
| Hamor, GP | 1 |
| Theobald, G | 1 |
| Nyberg, G | 1 |
| Lewis, RV | 2 |
| Ramsay, LE | 2 |
| Jackson, PR | 2 |
| Yeo, WW | 1 |
| Lennard, MS | 1 |
| Tucker, GT | 1 |
| Dimenäs, ES | 1 |
| Dahlöf, CG | 1 |
| Heibel, B | 1 |
| Moore, RG | 1 |
| Olofsson, BK | 1 |
| Westergren, GE | 1 |
| Lücker, PW | 1 |
| Dolva, LO | 1 |
| Kjeldsen, SE | 1 |
| Eide, I | 1 |
| Areskog, NH | 1 |
| Blomqvist, I | 1 |
| Westergren, G | 1 |
| Sandberg, A | 1 |
| Jonsson, UE | 1 |
| Lundborg, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses 2[NCT01203852] | Phase 4 | 839 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure[NCT04871178] | 50 participants (Actual) | Interventional | 2010-10-10 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in glucose after treatment with study medication (NCT01203852)
Timeframe: after 6-8 weeks treatment
| Intervention | mg/dL (Mean) | |
|---|---|---|
| glucose response to metoprolol (n=365) | glucose response to chlorthalidone (n=318) | |
| Adverse Metabolic Effects | 1.02 | 5.12 |
Response to blood pressure medication will be assessed by measuring blood pressure before and after treatment (NCT01203852)
Timeframe: after 6-8 weeks of treatment
| Intervention | mmHg (Mean) | |
|---|---|---|
| diastolic blood pressure response | systolic blood pressure response | |
| Chlorthalidone Only | -7.68 | -13.65 |
| Metoprolol + Chlorthalidone | -7.56 | -11.70 |
| Metorprolol Only | -7.97 | -7.45 |
1 review available for metoprolol and Lassitude
| Article | Year |
|---|---|
Muscle fatigue and beta-blockers--a review.
Topics: Adaptation, Physiological; Adrenergic beta-Antagonists; Animals; Atenolol; Dogs; Dose-Response Relat | 1983 |
13 trials available for metoprolol and Lassitude
| Article | Year |
|---|---|
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
beta-blocker use and diabetes symptom score: results from the GEMINI study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cognition; Diab | 2007 |
Metabolic and hormonal responses to exhaustive supramaximal running with and without beta-adrenergic blockade.
Topics: Adrenergic beta-Antagonists; Adult; Bupranolol; Epinephrine; Fatigue; Growth Hormone; Hormones; Huma | 1984 |
Atenolol 50 mg or metoprolol 200 mg - a comparison of antihypertensive efficacy, side effects and lipoprotein changes.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Fatigue; Female; Heart Rate; Humans; Hype | 1983 |
Comparison of sustained-release clonidine and long-acting propranolol in the treatment of hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Clonidine; Delayed-Action Preparations; Double-Blind Method; | 1982 |
Metoprolol administered once daily in the treatment of hypertension. A double-blind crossover comparison between conventional tablets and metoprolol Durules.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; F | 1981 |
Acute effects of beta blockade and exercise on mood and anxiety.
Topics: Adrenergic beta-Antagonists; Adult; Affect; Age Factors; Anxiety; Body Weight; Confusion; Depression | 1996 |
Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
Topics: Adult; Atenolol; Debrisoquin; Fatigue; Female; Humans; Male; Metoprolol; Oxidation-Reduction; Phenot | 1991 |
Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.
Topics: Aged; Atenolol; Delayed-Action Preparations; Double-Blind Method; Electrocardiography; Exercise Test | 1990 |
Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise.
Topics: Adrenergic beta-Antagonists; Adult; Blood Glucose; Blood Pressure; Dopamine; Epinephrine; Exercise; | 1989 |
Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.
Topics: Adult; Atenolol; Blood Pressure; Delayed-Action Preparations; Fatigue; Heart Rate; Humans; Male; Met | 1988 |
7 other studies available for metoprolol and Lassitude
| Article | Year |
|---|---|
Clinically important interaction between metoprolol and propafenone.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; | 2013 |
Management of labour and delivery in a woman with refractory supraventricular tachycardia.
Topics: Adult; Amides; Amnion; Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthesia, Epidural; Anes | 2014 |
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP2D6; Depression; Fatigue; Female | 2014 |
Case studies in heart failure.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Catheteriz | 2003 |
Limitation of work performance in normal adult males in the presence of beta-adrenergic blockade.
Topics: Adult; Blood Pressure; Fatigue; Fatty Acids, Nonesterified; Heart Rate; Hemodynamics; Humans; Lactat | 1979 |
Effects and adverse effects of autonomic blockade in physical exercise.
Topics: Adrenergic beta-Antagonists; Animals; Autonomic Nervous System; Fatigue; Heart Rate; Humans; Metopro | 1985 |
Side-effects of beta-blockers assessed using visual analogue scales.
Topics: Acebutolol; Adrenergic beta-Antagonists; Analysis of Variance; Atenolol; Dreams; Fatigue; Humans; Hy | 1985 |